|
US6362325B1
(en)
*
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US20060002904A9
(en)
*
|
1988-11-07 |
2006-01-05 |
Kwon Byoung S |
Receptor and related products and methods
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US20060063923A1
(en)
*
|
1992-07-30 |
2006-03-23 |
Kwon Byoung S |
4-1BB peptides and methods for use
|
|
CA2172165C
(en)
*
|
1993-09-16 |
2003-12-02 |
Byoung S. Kwon |
Human receptor h4-1bb
|
|
IL129138A0
(en)
*
|
1996-10-11 |
2000-02-17 |
Bristol Myers Squibb Co |
Methods and compositions for immunomodulation
|
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
|
US20030096976A1
(en)
*
|
1998-11-17 |
2003-05-22 |
Hong Hyo Jeong |
Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
|
|
KR20000034847A
(ko)
*
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
|
US20040001863A1
(en)
*
|
1998-12-03 |
2004-01-01 |
Shau-Chi Chi |
Immortal cell line derived from grouper Epinephelus coioides and its applications therein
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
CA2408408C
(en)
|
2000-05-12 |
2013-07-09 |
Genzyme Corporation |
Modulators of tnf- alpha signaling
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
AU2002364935A1
(en)
|
2001-10-09 |
2003-06-23 |
Mayo Foundation For Medical Education And Research |
Enhancement of immune responses by 4-1bb-binding agents
|
|
US20040109847A1
(en)
*
|
2002-07-15 |
2004-06-10 |
Lieping Chen |
Treatment and prophylaxis with 4-1BB-binding agents
|
|
JP2006500921A
(ja)
*
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト4−1bbに対するヒト化抗体
|
|
EP1388544A1
(de)
*
|
2002-07-31 |
2004-02-11 |
D. Collen Research Foundation vzw |
Anti-Idiotypische Antikörper gegen Factor VIII-Inhibitor und Verwendungen davon
|
|
WO2004019866A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Immunex Corporation |
Compositions and methods for treating cardiovascular disease
|
|
AU2003290059A1
(en)
*
|
2002-12-16 |
2004-07-09 |
Herbert Schwarz |
Use of cd137 antagonists for the treatment of tumors
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
US7674884B2
(en)
*
|
2003-12-10 |
2010-03-09 |
Novimmune S.A. |
Neutralizing antibodies and methods of use thereof
|
|
PL1810026T3
(pl)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
|
US20080019905A9
(en)
*
|
2005-02-18 |
2008-01-24 |
Strome Scott E |
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
|
|
US20060182744A1
(en)
*
|
2005-02-15 |
2006-08-17 |
Strome Scott E |
Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
|
ES2642787T3
(es)
*
|
2005-10-21 |
2017-11-20 |
Lfb Usa, Inc. |
Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
|
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
|
US20110229460A1
(en)
*
|
2008-05-01 |
2011-09-22 |
Gtc Biotherapeutics, Inc. |
anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
CA2783563A1
(en)
|
2009-12-07 |
2011-06-16 |
Decimmune Therapeutics, Inc. |
Anti-inflammatory antibodies and uses therefor
|
|
JP6162319B2
(ja)
|
2013-03-12 |
2017-07-12 |
デシミューン セラピューティクス,インコーポレイテッド |
ヒト化抗n2抗体
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3470081A1
(de)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
|
|
EP3066127A1
(de)
|
2013-11-06 |
2016-09-14 |
Bristol-Myers Squibb Company |
Pläne zur immuntherapeutischen dosierung und kombinationen davon
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
|
EP3331919A1
(de)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapie mit anti-ctla-4-antikörpern
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
SG11201906319XA
(en)
|
2017-01-20 |
2019-08-27 |
Magenta Therapeutics Inc |
Compositions and methods for the depletion of cd137+ cells
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
EP3645741A4
(de)
*
|
2017-06-25 |
2021-08-25 |
Systimmune, Inc. |
Anti-4-1bb-antikörper und verfahren zur herstellung und verwendung
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
TWI701259B
(zh)
*
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
4﹘1bb抗體及其製備方法和應用
|
|
JP7557367B2
(ja)
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
|
EP3713961A2
(de)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
EP3737743A1
(de)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
|
|
TW201932491A
(zh)
*
|
2018-01-22 |
2019-08-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗4-1bb抗體、其抗原結合片段及其醫藥用途
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
EA202092319A1
(ru)
|
2018-03-29 |
2021-03-04 |
Айовэнс Байотерапьютикс, Инк. |
Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
|
|
WO2019196868A1
(en)
*
|
2018-04-10 |
2019-10-17 |
Wuxi Biologics (Shanghai) Co., Ltd. |
A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
|
US12624086B2
(en)
|
2018-10-31 |
2026-05-12 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12453697B2
(en)
|
2018-11-05 |
2025-10-28 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
IL282775B1
(en)
|
2018-11-05 |
2026-05-01 |
Iovance Biotherapeutics Inc |
Selection of enhanced carrier-reactive T cells
|
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
CN114269370A
(zh)
|
2019-03-29 |
2022-04-01 |
迈斯特治疗公司 |
离体产生t细胞治疗剂的方法以及相关的组合物和方法
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
MX2022001027A
(es)
*
|
2019-07-26 |
2022-04-18 |
Abl Bio Inc |
Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
|
|
EP4048295A1
(de)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Genbearbeitung von tumorinfiltrierenden lymphozyten und deren verwendungen in der immuntherapie
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
EP4110799B1
(de)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Verfahren zur ex-vivo-anreicherung und vermehrung von tumorreaktiven t-zellen und verwandten zusammensetzungen davon
|
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
|
EP4146793A1
(de)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Auswahl von verbesserten tumorreaktiven t-zellen
|
|
WO2021226061A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3185200A1
(en)
*
|
2020-07-09 |
2022-01-13 |
Lankeanau Institute For Medical Research |
Compositions comprising antibodies to human ido-2
|
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
|
US20240299540A1
(en)
|
2021-02-05 |
2024-09-12 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
JP2024509184A
(ja)
|
2021-03-05 |
2024-02-29 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍保存及び細胞培養組成物
|
|
EP4314253A2
(de)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Verfahren und zusammensetzungen für t-zell-kokulturpotenztests und verwendung mit zelltherapieprodukten
|
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20240269180A1
(en)
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
US20250000903A1
(en)
|
2021-09-24 |
2025-01-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
JP2025503987A
(ja)
|
2022-01-28 |
2025-02-06 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
ペイロードを発現するように操作された腫瘍浸潤リンパ球
|
|
EP4507704A1
(de)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til-expansionsverfahren unter verwendung spezifischer zytokinkombinationen und/oder einer akti-behandlung
|
|
EP4565683A1
(de)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimäre kostimulatorische rezeptoren, chemokinrezeptoren und deren verwendung in zellulären immuntherapien
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
IL328125A
(en)
|
2023-11-06 |
2026-06-01 |
Iovance Biotherapeutics Inc |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|